Cannabis Bioscience International Holdings, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
OID
Cannabis Bioscience International Holdings, Inc. reported a reduced net loss for fiscal year 2025, driven by increased clinical trial revenue, while facing significant going concern doubts and a need for substantial capital.
OID
10-K: Cannabis Bioscience International Holdings Reports 10-K Filing, Cites Ongoing Financial Challenges
Cannabis Bioscience International Holdings' latest 10-K filing reveals a net loss of $651,345 for the fiscal year ending May 31, 2024, and highlights the company's ongoing efforts to navigate financial difficulties and expand its operations.